Hydra Biosciences, Cambridge, Massachusetts 02138, USA; email:
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:309-330. doi: 10.1146/annurev-pharmtox-010617-052832. Epub 2017 Sep 25.
The transient receptor potential (TRP) superfamily of channels comprises a diverse group of cation channels. Four TRP channel subunits coassemble to form functional homo- or heterotetramers that pass sodium, calcium, or both in the inward direction. Modulating TRP channel activity provides an important way to impact cellular function by regulating both membrane excitability and intracellular calcium levels. The import of these channels is underscored by the number of genetic diseases caused when they are mutated: Skeletal, skin, sensory, ocular, cardiac, and neuronal disturbances all arise from aberrant TRP function. Not surprisingly, there has been significant pharmaceutical interest in targeting these fascinating channels. Compounds that modulate TRP vanilloid 1 (TRPV1), TRPV3, TRPV4, TRP ankyrin 1 (TRPA1), and TRP melastatin 8 (TRPM8) have all entered clinical trials. The goal of this review is to familiarize the readers with the rationale behind the pursuit of these channels in drug discovery and the status of those efforts.
瞬时受体电位 (TRP) 通道超家族由一组多样化的阳离子通道组成。四个 TRP 通道亚基共同组装形成功能性同型或异型四聚体,以内向方式传递钠、钙或两者。调节 TRP 通道活性是通过调节膜兴奋性和细胞内钙水平来影响细胞功能的重要途径。这些通道的重要性体现在它们发生突变时会导致许多遗传疾病上:骨骼、皮肤、感觉、眼部、心脏和神经元紊乱均源于 TRP 功能异常。毫不奇怪,靶向这些迷人通道一直是制药领域的重要关注点。调节 TRPV1、TRPV3、TRPV4、TRPA1 和 TRPM8 的化合物均已进入临床试验。本文的目的是使读者熟悉在药物发现中针对这些通道的基本原理和研究进展。